Celularity is based in New Jersey. It has raised $280M in total funding. Latest round: Series C.
Celularity funding overview
Celularity is based in New Jersey. Celularity has raised $280M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in May 2022. The round record for Celularity runs through 2022; nothing later has been disclosed. Investors on record include Genting Berhad/Dragasac Limited, Philip A. Barach, Celgene, Sorrento Therapeutics, United Therapeutics Corporation, Human Longevity Inc. 6 distinct backers are named across the disclosed rounds.
Celularity at a glance
Total raised
$280M
Latest round
Series C
Latest round date
May 2022
Headquarters
New Jersey
Notable investors
Genting Berhad/Dragasac Limited, Philip A. Barach, Celgene, Sorrento Therapeutics, United Therapeutics Corporation, Human Longevity Inc
Frequently asked about Celularity funding
How much has Celularity raised?
Celularity has raised $280M in total disclosed funding across the rounds on record.
Who has invested in Celularity?
Genting Berhad/Dragasac Limited, Philip A. Barach, Celgene, Sorrento Therapeutics, United Therapeutics Corporation, Human Longevity Inc are named among the investors backing Celularity.
What was the latest Celularity funding round?
The most recent disclosed round is a Series C, announced in May 2022.
Where is Celularity based?
Celularity is based in New Jersey.
When did Celularity last raise?
The last disclosed Celularity round closed in May 2022 at Series C.
Totals shown for Celularity aggregate every disclosed round on file. To see how that compares, browse the companies in New Jersey and the investors behind them below.
